The Non-Alcoholic Steatohepatitis (NASH) Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Non-Alcoholic Steatohepatitis (NASH) Market?
The Non-Alcoholic Steatohepatitis (NASH) global market has notably expanded recently. The market size is projected to increase from $4.5 billion in 2024 to $6.13 billion in 2025, which corresponds to a 36.1% compound annual growth rate (CAGR).
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Non-Alcoholic Steatohepatitis (NASH) Industry?
The Non-Alcoholic Steatohepatitis (NASH) global market size is expected to grow to $19.07 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 32.8%.
Download Your Free Sample of the 2025 Non-Alcoholic Steatohepatitis (NASH) Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Non-Alcoholic Steatohepatitis (NASH) Market?
The key drivers in the non-alcoholic steatohepatitis (nash) market are:
• Advancements in NASH drug development
• Increasing initiatives for NASH screening
• Rising healthcare expenditure
• Collaborative efforts in research and government support.
Global Market Segmentation: Identifying Major Non-Alcoholic Steatohepatitis (NASH) Industry Segments
The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented –
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Pre-order the 2025 Non-Alcoholic Steatohepatitis (NASH) Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Non-Alcoholic Steatohepatitis (NASH) Market?
The key trends in the non-alcoholic steatohepatitis (nash) market are:
• There is a growing focus on lifestyle interventions and patient education in the NASH market.
• Increasing collaboration in clinical research is a major upcoming trend.
• The market is witnessing regulatory advancements and pathway designations.
• Integration of artificial intelligence in diagnosis and monitoring of NASH is a significant emerging trend.
Who Are the Top Competitors & Leading Players in the Non-Alcoholic Steatohepatitis (NASH) Market?
Major companies in the non-alcoholic steatohepatitis (nash) market are:
• NGM Biopharmaceuticals Inc.
• Novartis AG
• AstraZeneca plc.
• GlaxoSmithKline plc.
• F. Hoffmann-La Roche AG
• The Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Genfit SA
• Cadila Pharmaceuticals Ltd.
• Intercept Pharmaceuticals Inc.
• Enanta Pharmaceuticals Inc.
• Blade Therapeutics Inc.
• Galmed Pharmaceuticals Inc.
• Immuron Limited
• Terns Pharmaceuticals Inc.
• Tobira Therapeutics Inc.
• Arena Pharmaceuticals Inc.
• Galectin Therapeutics Inc.
• Viking Therapeutics
• Madrigal Pharmaceuticals Inc.
• Cirius Therapeutics
• Akero Therapeutics Inc.
• Echosens
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024
